Myovant Sciences Ltd. Common Shares (MYOV): Price and Financial Metrics
GET POWR RATINGS... FREE!
MYOV POWR Grades
- Value is the dimension where MYOV ranks best; there it ranks ahead of 74.12% of US stocks.
- The strongest trend for MYOV is in Value, which has been heading up over the past 48 weeks.
- MYOV ranks lowest in Sentiment; there it ranks in the 4th percentile.
MYOV Stock Summary
- Myovant Sciences Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 5.54% of US listed stocks.
- MYOV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 4.27% of US stocks.
- Revenue growth over the past 12 months for Myovant Sciences Ltd comes in at 101.14%, a number that bests 93.66% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Myovant Sciences Ltd, a group of peers worth examining would be AFIB, VIVE, PSTG, NSTG, and LPSN.
- MYOV's SEC filings can be seen here. And to visit Myovant Sciences Ltd's official web site, go to myovant.com.
MYOV Valuation Summary
- In comparison to the median Healthcare stock, MYOV's EV/EBIT ratio is 126.62% lower, now standing at -7.8.
- MYOV's price/earnings ratio has moved NA NA over the prior 59 months.
- Over the past 59 months, MYOV's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for MYOV.
MYOV's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- MYOV has a Quality Grade of C, ranking ahead of 69.77% of graded US stocks.
- MYOV's asset turnover comes in at 0.114 -- ranking 252nd of 677 Pharmaceutical Products stocks.
- GNCA, MEIP, and OCGN are the stocks whose asset turnover ratios are most correlated with MYOV.
The table below shows MYOV's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
MYOV Stock Price Chart Interactive Chart >
MYOV Price/Volume Stats
|Current price||$22.27||52-week high||$30.90|
|Prev. close||$22.09||52-week low||$13.42|
|Day high||$22.52||Avg. volume||817,849|
|50-day MA||$21.88||Dividend yield||N/A|
|200-day MA||$22.14||Market Cap||2.05B|
Myovant Sciences Ltd. Common Shares (MYOV) Company Bio
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. The company was founded in 2016 and is based in Hamilton, Bermuda.
Most Popular Stories View All
MYOV Latest News Stream
|Loading, please wait...|
MYOV Latest Social Stream
View Full MYOV Social Stream
Latest MYOV News From Around the Web
Below are the latest news stories about Myovant Sciences Ltd that investors may wish to consider to help them evaluate MYOV as an investment opportunity.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Asana The Trade: Asana,
Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
BASEL, Switzerland and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE ® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis. The FDA set a target action date of May 6, 2022 for this sNDA under the Prescription Drug User Fee Act (PDUFA).
BASEL, Switzerland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global Healthcare Conference on September 15, 2021. Company management will participate in a fireside chat at 2:35 p.m. Eastern Time in addition to participating in small group investor meetings.
Heavy Menstrual Bleeding (HMB) Market Amazing Demand 3X Revenues by 2021-2028 with ObsEva, AbbVie, Myovant Sciences, Bayer, Enteris BioPharma, Ferring Pharmaceuticals
Heavy menstrual bleeding (HMB) is one of the most common gynecological disorders affecting women of reproductive age. It is subjectively defined as heavy cyclical menstrual bleeding occurring over several consecutive cycles. As observed, it is a total blood loss of
MYOV Price Returns